What question did this study set out to answer?

To evaluate the association between modern Hodgkin lymphoma treatments and the risk of second primary malignancies (SPMs).

Modern Hodgkin lymphoma treatments to reduce second cancer risks: Influence of risk-adapted screening.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial assesses secondary cancer risks in Hodgkin lymphoma survivors, suggesting updated screening protocols.

To evaluate the association between modern Hodgkin lymphoma treatments and the risk of second primary malignancies (SPMs).
Assembled a national cohort of 7,428 women treated for HL aged <36 from England and Wales (1954-2010) with 99% follow-up until 2018.
Analyzed SPM incidence using national cancer registry linkage and treatment data from over 250 centers.
Calculated Standardized Incidence Ratios (SIRs) and conducted multivariable analyses to assess treatment impacts on SPMs.
1,200 women (16%) developed 1,467 SPMs during a mean follow-up of 22 years; overall SIR for any SPM was 3.3 (95% CI 3.1-3.5) with significant risks linked to breast cancer (AER 30.8, 95% CI 27.7-34.1).
Radiotherapy usage decreased from 98% (1954-1980) to 47% (2000-2010), while chemotherapy use increased from 55% to 97% during the same period.
There was a 25% overall reduction in SPM risk and a 34% reduction in solid SPMs from <1990 to 2000-2010, but risks remained significantly elevated even 40 years post-treatment.

Macklin-Doherty et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark